Next Phase Newsletter

This corporate strategic evergreen fund based in the US has invested in over 50 life sciences companies and considers both public and private opportunities in the United States and internationally. The firm is a flexible investor, with initial allocations typically ranging from $1 million to $10 million, depending on the developmental stage of the company. 

The firm invests in therapeutics and medical devices, with the latter limited to implantable products requiring PMA submission. It invests exclusively in companies with clinical-stage assets, and is indication-agnostic, open to innovation across all areas of medicine. 

This investor adopts a flexible approach to management teams, and is willing to take a more hands-on role in cases where founding teams have limited internal resources. A high level of transparency is required from portfolio companies, and the firm actively supports strategic planning around value-driving clinical studies that can meaningfully advance the company’s trajectory. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A Europe-based venture capital firm invests across two primary verticals: healthcare innovation and sustainability. The firm typically invests at the seed stage, with initial check sizes ranging from €1 million to €5 million. Its geographic deployment is relatively balanced, with approximately half of investments made in Europe and the other half in the United States. The firm shows particular interest in U.S.-based companies founded by European entrepreneurs. 

The firm invests across therapeutics, diagnostics, medical devices, and digital health, taking an agnostic approach within these sectors. It does not enforce strict criteria regarding the composition or background of founding teams. 

Open to both leading and co-investing, the firm places strong emphasis on the mission and purpose behind each company, placing value on teams with a compelling “why” that drives their approach to solving pressing problems in healthcare. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

This Western Europe-based investment firm has been active for over two decades and manages multi-billion in assets under management. The firm takes a sector-agnostic approach, investing across a broad spectrum including enterprise software, fintech, consumer technologies, deeptech, and life sciences. 

Typical equity investments range from $1 million to $10 million, and the firm expects to make several new investments annually. While companies must maintain a local operational presence in the firm’s home country, they may also have international footprints. 

In the life sciences and biotech space, the firm adopts a wide-angle lens, looking for companies developing drug discovery platforms, synthetic biology innovations, and enabling research technologies.  

The firm is open to investing in pre-revenue companies, and is supportive of both emerging and experienced founding teams. It frequently invests at the early growth stage, often in syndicate with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 
This venture capital firm focuses on breakthrough technologies transforming healthcare and typically invests at the pre-seed, seed, and pre-Series A stages. The firm is backed by limited partners from within the healthcare industry, reinforcing its domain expertise and strategic alignment with clinical innovation. 

The firm targets early-stage life science startups working at the intersection of cutting-edge science and healthcare applications. Areas of interest include genomic technologies, synthetic biology, digital health, machine learning and artificial intelligence, therapeutics, and diagnostics. In therapeutics, the firm focuses on pre-IND assets, while for technologies regulated as medical devices, the firm prioritizes smart devices at the pre-commercial stage. 

With a team that brings a strong clinical perspective, the firm actively supports its portfolio companies through clinical development and has a history of helping academic scientists translate research into commercial ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment firm headquartered in the US focuses on healthcare companies across the seed, venture, and growth stages. The firm typically provides seed and Series A equity financing ranging from $100K to $1M per portfolio company. While the firm often acts as a lead investor, it is also open to participating in syndicated rounds. The firm is open to investment opportunities throughout North America. The firm is actively seeking new investments. 

Current areas of interest include medical devices, diagnostics, digital health, and healthcare-focused software. The firm is also open to reformulated or repurposed drugs, particularly those with reduced development risk. In the medical device category, the firm remains opportunistic across subsectors, with a preference for products that have a prototype and follow the 510(k) regulatory pathway. The firm is indication-agnostic, with interest that includes orphan diseases and the dental field. 

The firm places a strong emphasis on working with experienced management teams and may take a board seat when appropriate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 
This growth-focused investment firm is headquartered in Europe, and was founded by entrepreneurs who previously built and exited a unicorn multinational company. With a renewed mission to drive innovation and growth, the firm targets both early-stage life science ventures and established professional service providers. 

In the early-stage segment, the firm typically invests up to €500K in Series A rounds and makes smaller allocations at the Seed stage. The investment strategy centers on innovative, tech-enabled, and service-oriented companies within the life sciences and healthcare sectors. While the firm is open to early-stage opportunities, it prefers companies with a proven business model and a clear path to scale. 

The firm is eager to partner with strong management teams developing solutions that address unmet needs with a compelling value proposition. Most investments are made as part of a syndicate with institutional venture capital firms, and the firm contributes beyond capital by offering deep sector expertise, an extensive network, and a strong entrepreneurial track record. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An angel syndicate is focused on life science tools and biotech infrastructure. The firm has a concentrated investment strategy targeting U.S.-based companies from the Pre-Seed to Series A stages. The firm’s investor base includes a select group of limited partners, about half of whom are active operators within the life science tools sector. The firm can co-invest but prefers to lead investments, with typical check sizes ranging from $160K to $2M. The firm brings deep domain expertise in life sciences and works closely with founders to build companies, pairing them with strategic capital. The firm is thesis-driven and leverages its extensive operator network, commercial reach, and M&A experience to accelerate company growth and strategy. The firm supports all aspects of business development, from financial modeling and strategic planning to connecting founders with key industry stakeholders within the life sciences ecosystem. 

The firm exclusively targets life science tools, software, biotech infrastructure, and platform technologies that typically include a consumable component. The firm does not invest in therapeutics, diagnostics, digital health, or any business requiring FDA clearance. The firm is open to all development stages and all classes of tools, software, and platform technologies. 

The firm only works with companies whose founders and teams are fully dedicated to their ventures. The firm generally prefers to take a board seat if it leads the investment round and if doing so aligns with the company’s stage of development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology